Title |
Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates
|
---|---|
Published in |
Journal of Pharmacokinetics and Pharmacodynamics, September 2017
|
DOI | 10.1007/s10928-017-9544-y |
Pubmed ID | |
Authors |
Matts Kågedal, Leonid Gibiansky, Jian Xu, Xin Wang, Divya Samineni, Shang-Chiung Chen, Dan Lu, Priya Agarwal, Bei Wang, Ola Saad, Neelima Koppada, Bernard M. Fine, Jin Y. Jin, Sandhya Girish, Chunze Li |
Abstract |
Antibody-drug conjugates (ADCs) developed using the valine-citrulline-MMAE (vc-MMAE) platform, consist of a monoclonal antibody (mAb) covalently bound with a potent anti-mitotic toxin (MMAE) through a protease-labile vc linker. Recently, clinical data for a variety of vc-MMAE ADCs has become available. The goal of this analysis was to develop a platform model that simultaneously described antibody-conjugated MMAE (acMMAE) pharmacokinetic (PK) data from eight vc-MMAE ADCs, against different targets and tumor indications; and to assess differences and similarities of model parameters and model predictions, between different compounds. Clinical PK data of eight vc-MMAE ADCs from eight Phase I studies were pooled. A population PK platform model for the eight ADCs was developed, where the inter-compound variability (ICV) was described explicitly, using the third random effect level (ICV), and implemented using LEVEL option of NONMEM 7.3. The PK was described by a two-compartment model with time dependent clearance. Clearance and volume of distribution increased with body weight; volume was higher for males, and clearance mildly decreased with the nominal dose. Michaelis-Menten elimination had only minor effect on PK and was not included in the model. Time-dependence of clearance had no effect beyond the first dosing cycle. Clearance and central volume were similar among ADCs, with ICV of 15 and 5%, respectively. Thus, PK of acMMAE was largely comparable across different vc-MMAE ADCs. The model may be applied to predict PK-profiles of vc-MMAE ADCs under development, estimate individual exposure for the subsequent PK-pharmacodynamics (PD) analysis, and project optimal dose regimens and PK sampling times. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 23 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 17% |
Student > Master | 3 | 13% |
Student > Ph. D. Student | 3 | 13% |
Lecturer | 1 | 4% |
Student > Doctoral Student | 1 | 4% |
Other | 3 | 13% |
Unknown | 8 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 6 | 26% |
Medicine and Dentistry | 3 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
Biochemistry, Genetics and Molecular Biology | 2 | 9% |
Decision Sciences | 1 | 4% |
Other | 1 | 4% |
Unknown | 8 | 35% |